NCT03514017 2026-03-02Ibrutinib and PD-1 Blockade in High Risk Lymphocytic LeukemiaH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Terminated5 enrolled 11 charts
NCT01345019 2022-11-08Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple MyelomaAmgenPhase 3 Completed1,718 enrolled 22 charts
NCT01667133 2022-06-13A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)TakedaPhase 1/2 Completed35 enrolled 36 charts
NCT02130557 2021-05-18A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaPfizerPhase 3 Completed536 enrolled 24 charts 1 FDA
NCT01773187 2020-09-29Pacritinib Versus Best Available Therapy to Treat MyelofibrosisCTI BioPharmaPhase 3 Terminated327 enrolled 11 charts
NCT01369498 2020-07-01Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia MyelofibrosisGilead SciencesPhase 2 Completed54 enrolled 16 charts
NCT01787552 2020-04-15A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFNovartisPhase 1/2 Completed50 enrolled 23 charts
NCT01201811 2019-12-05Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)CelgenePhase 4 Completed44 enrolled 26 charts
NCT01650805 2014-11-17Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)Ariad PharmaceuticalsPhase 3 Terminated307 enrolled 11 charts